Novacyt S.A.
("Novacyt", the "Company" or the "Group")
AGM voting
Paris, France and Camberley, UK - 13 September 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, will be holding its annual general meeting (AGM) as a closed meeting at 2pm CEST/1pm BST on Wednesday, 29 September 2021. As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary general meetings.
Due to precautionary measures put in place by the French Government as a result of the COVID-19 pandemic, and with the health and safety of its shareholders and employees being a priority, the AGM will be held without the physical presence of shareholders.
The Notice of AGM and a Form of Proxy have been posted to shareholders and are also available on the Company's website, together with an AGM registration form and a video explaining the voting process to shareholders. All materials can be found at www.novacyt.com/general-meetings. Shareholders are strongly encouraged to submit their proxy votes either by post, email or vote electronically in accordance with the instructions in the Notice.
Shareholders can register for the AGM and access to the online meeting by visiting https://novacytagm.eventitdept.com. Shareholders can vote online until midnight on Saturday, 25 September 2021 using the same link. Submissions must include an electronic signature and be accompanied by evidence of shareholding, for example a share certificate or statement of holding.
Shareholders can alternatively download a copy of the Proxy voting form from www.novacyt.com./general-meetings for completion and return to investor.relations@novacyt.com together with evidence of their holding.
Shareholders can also vote on-line until 3pm on Tuesday 28 September 2021 using the Votaccess portal www.actionnaire.cic-marketsolutions.eu/fr/identification if securities held on Euronext Growth are registered with any of the following banks: CIC, Natixis, Société Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank or Deutsche Bank.
Under French law, for the meetings to be quorate at the first attempt, at least 20% of shareholders must vote on the ordinary resolutions and 25% of shareholders must vote on the extraordinary resolutions.
Following registration, shareholders will be able to view the agenda and a live webcast of the AGM. Following the meeting, a recording of the AGM will be available on the Company's website at www.novacyt.com.
- End -
For further information, please refer to www.novacyt.com or contact:
Novacyt SA
Graham Mullis, Chief Executive Officer
James McCarthy, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
Freddie Barnfield / James Black
+44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com/ y.petit@allegrafinance.com
FTI Consulting (International)
Victoria Foster Mitchell / Alex Shaw
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com / Alex.Shaw@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
For more information please refer to the website: www.novacyt.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
